title: [Potential role of macrolides in the treatment of COPD: current evidence. (discussion)].
authors.forename: Yoshinosuke
authors.initials: Y
authors.lastname: Fukuchi
authors.forename: Shoji
authors.initials: S
authors.lastname: Kudo
authors.forename: Masakazu
authors.initials: M
authors.lastname: Ichinose
authors.forename: Mutsuo
authors.initials: M
authors.lastname: Yamatani
authors.forename: Terence A R
authors.initials: TA
authors.lastname: Seemungal
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D017291:Clarithromycin / Q000008:administration & dosage / Q000494:pharmacology; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D003864:Depression, Chemical; D004917:Erythromycin / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007155:Immunologic Factors; D018836:Inflammation Mediators / Q000378:metabolism; D018942:Macrolides / Q000008:administration & dosage* / Q000494:pharmacology; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D011991:Receptors, Virus / Q000187:drug effects; D018570:Risk Assessment
chemical_list: D000900:Anti-Bacterial Agents; D016207:Cytokines; D007155:Immunologic Factors; D018836:Inflammation Mediators; D018942:Macrolides; D011991:Receptors, Virus; D004917:Erythromycin; D017291:Clarithromycin